Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case

Estelle Nobecourt1, Bertrand Cariou2, Gilles Lambert3

  • 1Department of Endocrinology, Metabolic diseases and Nutrition, l'institut du thorax, CHU de Nantes, Nantes, France; CRNH, Human Nutrition Research Center, CHU, Nantes, France; INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, Nantes, France.

Journal of Clinical Lipidology
|April 11, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same author

Systematic evaluation of mobile element insertions in autosomal dominant hypercholesterolemia genes using short-read sequencing.

Atherosclerosis·2026
Same author

<i>LDLR</i>-3'UTR Deletions Identified as a Genetic Cause of Hypobetalipoproteinemia: Evidence From Familial and Population-Based Studies.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease - the ACTIDIANE randomized controlled trial.

Diabetes & metabolism·2026
Same author

Risk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope.

Diabetes & metabolism·2026
Same author

Lipidomics analysis to assess metabolic complications in familial partial lipodystrophy type 2.

Diabetes research and clinical practice·2026
This summary is machine-generated.

A rare condition, drug-induced low high-density lipoprotein cholesterol (HDL-C) can occur. Combining fibrates and ezetimibe may increase risk, necessitating careful HDL-C monitoring in patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Lipidology

Background:

  • Familial hypercholesterolemia and mixed dyslipidemia are common lipid disorders.
  • Statins and fibrates are frequently used to manage dyslipidemias.
  • Drug-induced decreases in high-density lipoprotein cholesterol (HDL-C) are rare.

Observation:

  • Two patients with familial hypercholesterolemia on statins and fibrates, and two with mixed dyslipidemia on fibrates, experienced severe HDL-C drops (-44% to -95%).
  • Three patients on fibrates experienced a sudden HDL-C decrease after adding ezetimibe.
  • HDL-C levels normalized upon discontinuation of the implicated medications.

Findings:

  • A combination therapy of fibrates and ezetimibe was associated with a sudden and severe decrease in HDL-C in susceptible patients.
Keywords:
Cardiovascular diseaseEzetimibeFibratesHDL-C

Related Experiment Videos

  • Reintroducing ezetimibe alone did not impact HDL-C levels in two patients, suggesting a synergistic effect with fibrates.

    • Implications:

    • Identifies a new patient profile at risk for significant HDL-C reduction due to combined fibrate and ezetimibe therapy.
    • Recommends close monitoring of plasma HDL-C levels in patients prescribed both fibrates and ezetimibe.
    • Highlights the importance of pharmacovigilance for rare but severe adverse drug reactions affecting lipid profiles.